Highest-materiality recent filing
Sana Biotechnology sells $25M in stock to Mayo Clinic with option for additional $25M
Issued 7,507,507 shares at $3.33 each to Mayo Clinic for ~$25M gross proceeds; closing expected April 15, 2026.
UP421 hypoimmune islet cells in type 1 diabetes show C-peptide production, immune evasion at 1 year without immunosuppression.
Sana: UP421 survives 12 months in T1D with no immunosuppression; plans SC451 IND, SG293 data in 2026
UP421, a hypoimmune pancreatic islet cell therapy, continued to survive and function at 12 months post-transplant in a T1D patient with no immunosuppression.
Q3 net loss $42.2M ($0.16/share); cash $153.1M; raised $115.8M in Q3, pro forma cash $170.5M.
Sana Biotechnology Q2 loss $0.39/sh (GAAP); positive type 1 diabetes cell therapy data; raises $105M
Net loss $93.8M ($0.39/sh GAAP); non-GAAP net loss $38.9M ($0.16/sh) vs $74.2M ($0.32/sh) year ago.
Sana Biotechnology prices $75M public offering of common stock and pre-funded warrants
Priced 20,895,522 shares at $3.35/share and 1,492,537 pre-funded warrants at $3.3499/underlying share.
Sana reports $90.1M cash, $40-45M facility impairment; positive UP421 data at 6 months
Cash, cash equivalents and marketable securities ~$90.1M as of July 31, 2025.
Six-month results: transplanted allogeneic islet cells (UP421) safe, survive, evade immune system, produce insulin without immunosuppression.
Sana reports Q1 net loss $49.4M, cash runway into 2026; new $119M ATM facility
Net loss $49.4M ($0.21/share) vs $107.5M ($0.49/share) in Q1 2024; loss narrowed.
Sana reports Q4 net loss $49.1M; positive T1D islet cell data at 12 weeks
HIP-modified islet cells (UP421) produced C-peptide and MMTT response at 12 weeks without immunosuppression; no safety issues.
Sana Biotechnology Q3 2024 net loss $59.9M; advancing three clinical programs; cash runway into 2026
Net loss of $59.9M ($0.25/sh) for Q3 2024 vs net income of $1.0M in Q3 2023.
Sana Biotechnology CFO Nathan Hardy resigns; CEO Harr named acting PFO, Susan Wyrick acting CFO
CFO Nathan Hardy resigned effective Oct 4, 2024; acting appointments made same day.
CFO Nathan Hardy resigns effective October 4, 2024
Nathan Hardy notified resignation as EVP and CFO on September 6, 2024, effective October 4, 2024.
Sana Q1 net loss $107.5M; cash $311M after $189.8M financing; four trials on track for 2024
Net loss GAAP $107.5M ($0.49/share) vs $82.1M ($0.43) YoY; adjusted net loss $69.5M ($0.32).
Sana Biotechnology R&D President Douglas Williams resigns effective April 18, 2024
Douglas Williams, Ph.D., resigned as EVP and President, Research and Development.
Q4 2023 net loss $88.1M ($0.45/share); full year net loss $283.3M ($1.46/share).
Sana Biotechnology prices upsized $165M public offering of common stock and pre-funded warrants
Sold 17.3M shares at $5.50 and pre-funded warrants for 12.7M shares at $5.4999 each.
Sana reports SC291 ARDENT interim data with responses and immune evasion; cash $205.4M
Preliminary cash, cash equivalents and marketable securities as of Jan 2, 2024: approximately $205.4 million.
Sana Biotechnology Q3 2023 GAAP net income $1.0M; cash $268.6M, pipeline data expected 2023-2024
Q3 2023 GAAP net income $1.0M driven by $82.6M gain from fair value changes on success payment liabilities.
Sana cuts workforce 29%, delays SG299 IND; 2024 cash burn under $200M
Workforce reduction of ~29%; expects 2024 operating cash burn below $200 million.
Sana Q2 net loss $114M ($0.59/shr); cash $325.9M; SC291 enrollment ongoing, data expected H2 2023
Net loss of $114M in Q2 2023 vs $72.5M in Q2 2022; six-month net loss $196.1M.
Douglas Williams, Ph.D., appointed EVP & President, R&D effective April 10, 2023; previously CEO of Codiak BioSciences.
Sana reports Q4 net loss $80.4M; cash $434M; SC291 IND cleared, expects clinical data this year
Net loss Q4 2022 $80.4M ($0.42/sh) vs $110.7M ($0.60/sh) in Q4 2021; FY2022 net loss $269.5M ($1.43/sh).
FDA clears Sana's IND for SC291 allogeneic CAR T therapy in B-cell malignancies
SC291 is a CD19-targeted allogeneic CAR T cell therapy using Sana's hypoimmune platform.
FDA cleared IND for SC291, a CD19-targeted allogeneic CAR T therapy using Sana's hypoimmune platform, in patients with B-cell lymphomas or leukemias.
Sana Biotech prioritizes pipeline, cuts 15% staff, halts SC187; maintains cash runway into 2025
Headcount reduced by ~15%; expects ~$7.9M in cash severance and ~$2.2M non-cash stock-based comp charges.
Sana Biotechnology reports Q3 net loss $85.1M; cash $511.6M; pipeline IND timeline updates
Net loss of $85.1M ($0.45 per share) vs $83.3M ($0.46 per share) in Q3 2021; cash, cash equivalents and marketable securities $511.6M at Sep 30, 2022.
Sana Q2 net loss $72.5M; cash runway extended into 2025 on manufacturing move savings
Cash position $579.6M at June 30, 2022, down $167.3M from Dec 31, 2021.
Nathan Hardy’s resignation as Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer (“PFO”), and Principal Accounting Officer (“PAO”)
Susan Wyrick, the Company’s Senior Vice President, Finance and Accounting, was appointed to serve as Acting Chief Financial Officer, Treasurer, and PAO
Steven D. Harr, M.D., the Company’s President and Chief Executive Officer, was appointed to serve as acting PFO in addition to his role as President and Chief Executive Officer.
On September 6, 2024, Nathan Hardy notified Sana Biotechnology, Inc. (the “Company”) that he intends to resign from his position as Executive Vice President and Chief Financial Officer of the Company effective October 4, 2024.
Effective April 18, 2024, Douglas Williams, Ph.D. resigned from his position as Executive Vice President and President, Research and Development of Sana Biotechnology, Inc. (the “Company”).
Sana Biotechnology, Inc. (the “Company”) previously filed a Current Report on Form 8-K disclosing the resignation of Sunil Agarwal, M.D. as the Company’s Executive Vice President, Head of Development, and Chief Medical Officer.
Sunil Agarwal, M.D. resigned from his position as Executive Vice President, Head of Development, and Chief Medical Officer of the Company, effective as of April 10, 2023.
Douglas E. Williams, Ph.D., has been appointed and will join the Company as Executive Vice President and President, Research and Development, effective April 10, 2023.
On September 1, 2021, Geoffrey von Maltzahn, Ph.D. notified Sana Biotechnology, Inc. (“Sana”) of his decision to resign from the Board of Directors of Sana (the “Board”), effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event other_material